Vaxart reported favorable 12-month safety data from the 400-participant sentinel cohort of its Phase II-B COVID-19 vaccine trial, with no vaccine-related serious complications. The larger, roughly 5,000-participant main cohort is fully enrolled, and top-line data are expected in the first half of 2027, pending BARDA approval. BARDA provided $29 million to fund expanded safety, immunogenicity, and efficacy analyses, including mucosal antibody testing, cellular biomarkers, and genomic sequencing across the main study cohort. Vaxart ended the second quarter of 2026 with $64 million in cash and short-term investments, enough to fund operations into the second quarter of 2027 under its current plan. The company is still seeking a norovirus vaccine partner and has revised board leadership and committee structures following a shareholder cooperation agreement.
Vaxart IncFavorable 12-month safety data from COVID-19 vaccine trial supports product viability.
